Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

NCT05345691 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

479

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis

Interventions

BIOLOGICAL: Bmab 1000
BIOLOGICAL: Prolia®

Sponsor

Biocon Biologics UK Ltd